BSECompany Update5d ago · 4 Nov 2026, 12:37 pm

This is with reference to the queries/clarification sought by NSE regarding Point F of Explanatory Statement 1 & 2 in relation to the object of the Preferential Issue.

Natural Capsules Ltd · 524654

✦ AI SummaryFundraise

Natural Capsules Ltd clarifies the object of the Preferential Issue, stating that the proceeds will be used for working capital requirements and capital expansion, including acquisition/establishment of a new unit.

Analysis Scores

Earnings Impact6/10
Growth Catalyst7/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk4/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Natural Capsules Ltd - 524654 - Clarification Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Clarification On Object Of The Issue Given On The Corrigendum Notice.

Attachments (1)

📄

a407af1b-31df-4e8a-a73e-97f874ed5f38.pdf

pdf

Download →
View document text
A C C R E D I T E D ISO/IEC 17021 CERTIFICATION BODY Date: November 04, 2026 To To BSE Limited National Stock Exchange of India Limited 25th Floor, PJ Towers Exchange Plaza, C-1, Block G Dalal Street, Bandra Kurla Complex, Bandra (E) Mumbai – 400001 Mumbai – 400051 Scrip Code: 524654 Symbol: NATCAPSUQ Sub: Clarification under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Clarification on Object of the Issue given on the Corrigendum Notice. This is with reference to the queries/clarification sought by BSE Limited and National Stock Exchange of India Limited regarding Point F of the Explanatory Statement 1 & 2 in relation to the Object of the Preferential Issue. To remove any ambiguity/confusion mentioned in the bifurcation and note to the Object of the Issue, the Company hereby provides a simplified clarification regarding the intended utilization of proceeds from the Preferential Issue of Equity Shares and Convertible Warrants: Clarification on Explanatory Statement to Item No 1 Point F: The Objects of the issue through preferential offer: The Company intends to utilize the proceeds raised through the Preferential Issue (“Issue Proceeds”) of ₹ 2,00,25,000 towards the Working Capital Requirements and Capital Expansion, including acquisition/establishment of new unit. The Company proposes to utilise the funds to meet its working capital requirements arising in the ordinary course of business. This includes expenses towards employee salaries, operational costs, and procurement of raw materials, vendor and service provider payments. The funds will also be used for marketing, logistics, rent, insurance, statutory and compliance costs, as well as advances and deposits required for smooth business operations. (“Working Capital Requirements”), and for exploring new business avenues for Capital Expansion. The Company intends to utilize the proceeds raised through the Preferential Issue towards Working Capital Requirements and Capital Expansion A. Working Capital Requirements: The Company proposes to utilize the funds to meet its working capital requirements arising in the ordinary course of business. This includes expenses towards procurement of raw materials, vendor payments, operational costs, employee salaries, marketing, logistics, rent, insurance, statutory and compliance costs, as well as advances and deposits required for smooth business operations. B. Capital Expansion: The proceeds will be allocated towards Capital Expansion to support long-term strategic growth. This includes: 1. Capacity Addition & Modernization: Enhancing existing manufacturing capabilities, upgrading plant machinery, and investing in process automation and technology to meet growing demand. 2. Strategic Growth & Business Avenues: Exploring potential expansion opportunities, including the preliminary evaluation of acquiring or establishing additional new unit to expand operational scale. A C C R E D I T E D ISO/IEC 17021 CERTIFICATION BODY Clarification to Explanatory Statement to Item No 2 Point F: The Objects of the issue through preferential offer: The Company intends to utilize the proceeds raised through the Preferential Issue (“Issue Proceeds”) of ₹ 8,01,00,000 towards the Working Capital Requirements and Capital Expansion, including acquisition/establishment of new unit. The Company proposes to utilise the funds to meet its working capital requirements arising in the ordinary course of business. This includes expenses towards employee salaries, operational costs, and procurement of raw materials, vendor and service provider payments. The funds will also be used for marketing, logistics, rent, insurance, statutory and compliance costs, as well as advances and deposits required for smooth business operations. (“Working Capital Requirements”), and for exploring new business avenues for Capital Expansion. The Company intends to utilize the proceeds raised through the Preferential Issue towards Working Capital Requirements and Capital Expansion A. Working Capital Requirements: The Company proposes to utilize the funds to meet its working capital requirements arising in the ordinary course of business. This includes expenses towards procurement of raw materials, vendor payments, operational costs, employee salaries, marketing, logistics, rent, insurance, statutory and compliance costs, as well as advances and deposits required for smooth business operations. B. Capital Expansion: The proceeds will be allocated towards Capital Expansion to support long-term strategic growth. This includes: 1. Capacity Addition & Modernization: Enhancing existing manufacturing capabilities, upgrading plant machinery, and investing in process automation and technology to meet growing demand. 2. Strategic Growth & Business Avenues: Exploring potential expansion opportunities, including the preliminary evaluation of acquiring or establishing additional new unit to expand operational scale. Yours Faithfully, For Natural Capsules Limited Akshay Dutta Company Secretary and Compliance Officer M.No. A80481